ArticleJournal of pharmacokinetics and pharmacodynamics2012
Modeling of red blood cell life-spans in hematologically normal populations.
Article in Journal of pharmacokinetics and pharmacodynamics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- A semi-mechanistic population pharmacokinetic-pharmacodynamic model to assess downstream drug-target effects on erythropoiesis.Journal of pharmacokinetics and pharmacodynamics · 2025Trial
- Population pharmacokinetics and pharmacodynamics of IONIS-GCGRJournal of pharmacokinetics and pharmacodynamics · 2017Trial
- Weight-HbA1c-insulin-glucose model for describing disease progression of type 2 diabetes.CPT: pharmacometrics & systems pharmacology · 2016Trial
- A Review of Semi-Mechanistic HbA1c Models in People with Type 2 Diabetes: Strengths, Limitations, and Applications.Journal of clinical pharmacology · 2026Review
- The Relationship between Hemoglobin A1c and the Glucose Management Indicator and Glucose Metrics in Children and Adolescents with Type 1 Diabetes Mellitus Using Automated Insulin Delivery SystemsJournal of clinical research in pediatric endocrinology · 2026Observational
- Integrated Longitudinal Population Dose-Hemoglobin Response of Daprodustat Following Dose Titration in Patients With Anemia in Chronic Kidney Disease.Clinical pharmacology and therapeutics · 2025Article
- Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa.Parasites & vectors · 2021Article
- Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes.CPT: pharmacometrics & systems pharmacology · 2018Article
- Age-structured population model of cell survival.Journal of pharmacokinetics and pharmacodynamics · 2017Article
- Glycated Hemoglobin, Plasma Glucose, and Erythrocyte Aging.Journal of diabetes science and technology · 2016Article
- Models for the red blood cell lifespan.Journal of pharmacokinetics and pharmacodynamics · 2016Article
- Use of an oral stable isotope label to confirm variation in red blood cell mean age that influences HbA1c interpretation.American journal of hematology · 2015Article
- Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations.Journal of pharmacokinetics and pharmacodynamics · 2014Article
- Effects of IL-1β-Blocking Therapies in Type 2 Diabetes Mellitus: A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms.CPT: pharmacometrics & systems pharmacology · 2014Article
- Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments.CPT: pharmacometrics & systems pharmacology · 2013Article
- A semi-mechanistic red blood cell survival model provides some insight into red blood cell destruction mechanisms.Journal of pharmacokinetics and pharmacodynamics · 2013Article
- A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects.Journal of pharmacokinetics and pharmacodynamics · 2013Article
- A pharmacokinetic model for the glycation of albumin.Journal of pharmacokinetics and pharmacodynamics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the impact of red blood cell (RBC) Life-spans in some disease areas such as diabetes or anemia of chronic kidney disease, there is no consensus on how to quantitatively best describe the process. Several models have been proposed to explain the elimination process of RBCs: random destruction process, homogeneous life-span model, or a series of 4-transit compartment model. The aim of this work was to explore the different models that have been proposed in literature, and modifications to those. The impact of choosing the right model on future outcomes prediction--in the above mentioned areas--was also investigated. Both data from indirect (clinical data) and direct life-span measurement (biotin-labeled data) methods were analyzed using non-linear mixed effects models. Analysis showed that: (1) predictions from non-steady state data will depend on the RBC model chosen; (2) the transit compartment model, which considers variation in life-span in the RBC population, better describes RBC survival data than the random destruction or homogenous life-span models; and (3) the additional incorporation of random destruction patterns, although improving the description of the RBC survival data, does not appear to provide a marked improvement when describing clinical data.
Indexed as
Identifiers
22847734What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.